Rafael Holdings, a biotech company developing treatments including remibetadex for Niemann-Pick Disease Type C, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026. The company recently submitted a New Drug Application to the FDA for remibetadex after completing a pivotal Phase 3 study. This event offers Rafael a platform to engage with institutional investors and discuss its clinical progress and future plans. A live webcast and replay will be available for broader access.
Rafael Holdings' participation in the Guggenheim Healthcare Innovation Conference is the subject here. For readers following the health sector, 118 of 150 priced US health stocks on Pluang rose today while 32 fell. Notable movers include Definium Therapeutics Inc. at USD 33.98 (+5.96%), Maravai LifeSciences Holdings Inc. at USD 7.62 (+5.91%), and Travere Therapeutics Inc. at USD 46.45 (-5.70%). This data is as of Nov 03, 2026 23:21 WIB.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
The Hospitality Show, a key event for hotel operations, will return to Las Vegas from March 27–29, 2028, at the Las Vegas Convention Center. This marks a return to its original location and an earlier spring date, chosen to better align with hospital...
FarmQA and Planet Labs have partnered to develop AI-powered agronomic tools for enterprise agriculture, starting with a sugar beet yield estimation model. This model combines Planet's satellite imagery with FarmQA's field-verified agronomic data to p...
The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...
